Results 171 to 180 of about 47,200 (309)

Dabigatran Reversal with Idarucizumab

New England Journal of Medicine, 2017
Pollack, Charles V., Reilly, Paul A, Weitz, Jeffrey I   +2 more
openaire   +7 more sources

The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin

, 2009
A. John Camm
openalex   +1 more source

PCV8 Cost-Effectiveness and Budget Impact Analysis of Rivaroxaban in the Prevention of Thromboembolic Events in Patients Performing Hip and Knee Arthroplasty in Comparison with Dabigatran Under the Brazilian Private Health Care System Perspective [PDF]

, 2011
Alexandre Schiola, A.P. Silva, N.B. Santoni, L. Paladini, V Teich, C. Pepe, Marinalva Soares de Oliveira Rocha   +6 more
openalex   +1 more source

Pharmacokinetics and bioequivalence of the generic and original dabigatran etexilate after a single dose in healthy volunteers

Российский кардиологический журнал
Aim. To study the comparative pharmacokinetics and confirmation of bioequivalence of the generic (T) and original (R) dabigatran etexilate in healthy volunteers after a single oral dose under fasted conditions.Material and methods.
V. B. Vasilyuk, M. V. Faraponova, A. B. Verveda, G. I. Syraeva, Yu. B. Vikharev, A. V. Popov, A. L. Kovalenko   +6 more
doaj   +1 more source

PCV114 DABIGATRAN ETEXILATE IS COST-SAVING FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS FOLLOWING MAJOR ORTHOPAEDIC SURGERY IN THE NETHERLANDS

, 2009
Cornelis Boersma, B.S. Kappelhoff, Maarten J. Postma   +2 more
openalex   +1 more source

Dabigatran como posibilidad terapéutica en el síndrome de trombocitopenia inducida por heparina tipo II [PDF]

, 2012
F. J. Anniccherico, J.L. Alonso, M. Urbieta, S. Pérez Ricarte   +3 more
openalex   +1 more source

Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study [PDF]

, 2015
BACKGROUND & AIMS: Use of dabigatran, an inhibitor of thrombin, increases the risk of gastrointestinal bleeding (GIB). However, it is not clear whether gastroprotective agents (GPAs) prevent GIB in dabigatran users.
Chan, EW, He, Y, Lau, WC, Leung, WK, Mok, MT, Tong, TS, Wong, IC   +6 more
core  

PCV2 Comparative Efficacy and Safety Analysis of Atrial Fibrillaion Patients Treated with Dabigatran in RE-LY Study (CHADS 2 Score of 3 or Greater ) Versus Rivaroxaban in ROCKET-AF [PDF]

, 2012
S. Rasty, W. Soliman, Reza Taheri
openalex   +1 more source

PCV112 COST EFFECTIVENESS OF RIVAROXABAN AND DABIGATRAN ETEXILATE FOR THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AND ASSOCIATED LONG TERM COMPLICATIONS POST TOTAL HIP REPLACEMENT IN IRELAND

, 2009
Laura McCullagh, Lesley Tilson, Cathal Walsh, Michael Barry   +3 more
openalex   +1 more source

Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation

Journal of the Formosan Medical Association, 2019
Background/purpose: Dabigatran is effective in preventing ischemic stroke and systemic embolism in patients with atrial fibrillation. Although the therapeutic window for dabigatran is wide, its pharmacokinetic properties can differ between specific ...
Shin-Yi Lin, Sung-Chun Tang, Ching-Hua Kuo, Li-Kai Tsai, Shin-Joe Yeh, Li-Jiuan Shen, Jiann-Shing Jeng   +6 more
doaj